Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248479 · ClinicalTrials.gov registry record · Phase 1
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 258
- Enrollment target
NCT03248479 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 258 participants.
The verdict
NCT03248479, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 258 participants
- Enrollment target
Study Summary
The primary objectives of this study are: * To confirm the safety and tolerability of magrolimab monotherapy in a relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) population, and of magrolimab in combination with azacitidine in previously untreated participants with AML or MDS and participants with R/R AML and MDS * To evaluate the efficacy of magrolimab monotherapy in R/R AML/MDS, and of magrolimab in combination with azacitidine in previously untreated participants with AML/MDS, or R/R AML/MDS as measured by complete remission (CR) rate for participants with AML and higher-risk MDS, and duration of complete response for participants with AML and higher-risk MDS, and duration of CR for participants with AML and higher-risk MDS * To evaluate the safety, tolerability, and efficacy of magrolimab monotherapy or combination with azacitidine in low-risk MDS participants as measured by red blood cell (RBC) transfusion independence rate
Interventions
- DRUG Azacitidine
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2017-09-08 |
| Est. Completion | 2023-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03248479
The ClinicalTrials.gov registry entry for NCT03248479 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT03248479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03248479 about?
NCT03248479 is a clinical study titled "Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies". The primary objectives of this study are: * To confirm the safety and tolerability of magrolimab monotherapy in a relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) population, and of magrolimab in combination with azacitidine in previously untreated participa...
What is the current status of trial NCT03248479?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 258 participants. The study started on 2017-09-08. Estimated completion is 2023-09-05.
What interventions are being tested in trial NCT03248479?
The interventions under investigation include: Azacitidine (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT03248479?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.